74773-28-7

Basic information

• Product Name: 2,4-Thiazolidinedione, 5-[[4-(cyclopropylmethoxy)phenyl]methyl]-
• CAS NO: 74773-28-7
• Molecular Formula: C14H15NO3S
• Molecular Weight: 277.344
• Mol File: 74773-28-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2,4-Thiazolidinedione, 5-[[4-(cyclopropylmethoxy)phenyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Thiazolidinedione, 5-[[4-(cyclopropylmethoxy)phenyl]methyl]-(74773-28-7)
• EPA Substance Registry System: 2,4-Thiazolidinedione, 5-[[4-(cyclopropylmethoxy)phenyl]methyl]-(74773-28-7)

Safety Data

• Hazardous Substances Data: 74773-28-7(Hazardous Substances Data)

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 164520-99-4 4-(cyclopropylmethoxy)benzaldehyde 
• 85003-34-5 2-Chloro-3-(4-cyclopropylmethoxy-phenyl)-propionic acid methyl ester 
• 17356-08-0 thiourea 
• 85002-74-0 1-{(cyclopropyl)methoxy}-4-nitrobenzene 
• 122828-48-2 4-(cyclopropylmethoxy)benzenamine 

Relevant articles and documents

Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium

Depletion of calcium from the endoplasmic reticulum has shown to affect protein synthesis and cell proliferation. The anticancer effect of troglitazone was reported to be mediated by depletion of intracellular calcium stores resulting in inhibition of translation initiation. The unsaturated form of troglitazone displays similar anticancer properties in vitro. In this letter, we report our findings on the minimum structural requirements for both compounds to retain their calcium release and antiproliferative activities.